Galmed Pharmaceuticals announced a research collaboration with Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor Aramchol as a targeted therapy for metastatic brain cancer, based on recent genomic findings linking p53 inactivation to SCD1 upregulation.
Key takeaways
Galmed entered a research collaboration with Ramot at Tel Aviv University to evaluate Aramchol for metastatic brain cancer treatment.
The collaboration is based on TAU research identifying SCD1 upregulation as essential for brain-metastasizing cells in p53-deficient tumors.
Aramchol is described as a first-in-class brain-penetrating SCD1 inhibitor, potentially positioning it for CNS diseases including brain metastases.
The research aims to validate Aramchol's efficacy using advanced 3D in vitro and in vivo models from TAU's internationally renowned labs.
Findings may support ongoing clinical work at Virginia Commonwealth University's Massey Comprehensive Cancer Center in colorectal cancers.